ONCOCROSS

  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

CONTACT US
  • KR
  • EN
  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

  • KR
  • EN
CONTACT US
  • Main
  • News/IR
  • Press Releases

Sina

韩国AI新药企业Oncocross完成约1400万美元B轮融资

  • 09-08-2020
https://mp.weixin.qq.com/s?__biz=Mzg2OTY4MTEzMA==&mid=2247525292&idx=3&sn=3fcb1624b6c843efa16343da68ec7c60&source=41#wechat_redirect
Previous
'AI신약연구' 온코크로스, VC업고 '제약 협업' 선도 09-09-2020
Next
`AI 신약벤처` 온코크로스, 165억 유치 성공 09-07-2020
List

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
Room 905, 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, Korea (Munjeong-dong, Munjeong Hyundai Knowledge Industry Center 1-2)
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.